Effect of traditional medicine protocol included Astraglus gossypinus with Ferula assa capsule on improvement of COVID-19 outpatients symptoms

Evaluation of the effect of traditional medicine protocol included Astraglus gossypinus with Ferula assa capsule on improvement of COVID-19 outpatients symptoms treated with conventional protocol

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101219005416N3

Enrollment

120

Registered

2020-08-26

Start date

2020-08-10

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. Confirmed COVID-19

Interventions

Intervention 1: Control group: Hospitalized patients are receiving standard corona treatment. Intervention 2: Intervention group: Patients admitted to hospital in addition to receiving standard treat

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: The patients that confirmed COVID- 19 with specialist on the base of CT changing or pharyngeal specimen or clinical symptoms

Exclusion criteria

Exclusion criteria: Lack of informed consent, Pregnancy, Breastfeeding

Design outcomes

Primary

Measure	Time frame
Response to the treatment (Significant clinical improvement). Timepoint: At baseline and daily. Method of measurement: Based on clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2 ° C), respiratory rate (=24 breaths per minute), cough; dyspnea; headche and dirrhea that will measure on a qualitative scale based on the patient's report. Other outcome variables will measure during clinical examination.	—

Measure

Time frame

Response to the treatment (Significant clinical improvement). Timepoint: At baseline and daily. Method of measurement: Based on clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2 ° C), respiratory rate (=24 breaths per minute), cough; dyspnea; headche and dirrhea that will measure on a qualitative scale based on the patient's report. Other outcome variables will measure during clinical examination.

—

Secondary

Measure	Time frame
Mortality. Timepoint: End of the treatment. Method of measurement: Ratio of the number of deaths to total patients in each group.;Hospital admssion. Timepoint: End of the treatment. Method of measurement: Ratio of the number of admission to total patients in each group.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHaleh Tajadini

Kerman University of Medical Sciences

drhalehtajadini@gmail.com+98 34 3243 5539

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026